Advancements in targeted gene therapy and immunotherapy are transforming cancer treatments with unprecedented precision. These cutting-edge therapies provide new treatment options for patients with rare or refractory tumors, reducing the need for invasive procedures and minimizing side effects. This progress brings new hope to patients worldwide. Shanghai Yuansong Biotechnology is making significant strides in the biopharmaceutical industry with its groundbreaking approach to cancer treatment. The company specializes in developing oncolytic viruses (OV), which create therapies that selectively target and destroy cancer cells while sparing healthy tissues. This innovative strategy, known as Cancer-Targeted Gene-Virotherapy Therapy (CTGVT), combines gene therapy with oncolytic virus therapy to enhance treatment efficacy in the past 24 years. The company’s clinical progress underscores the uniqueness of its methods and products, setting it apart from competitors and establishing a strong foothold in the industry. “Our mission is to push the boundaries of cancer treatment by leveraging our distinctive capabilities and integrating cutting-edge gene and virus therapies,” says Dr. Kang-jian Zhang, CEO and co-founder at Shanghai Yuansong Biotechnology. Transforming Cancer Therapy with Oncolytic Viruses based on CTGVT strategy Demonstrating Shanghai Yuansong’s innovative expertise is its flagship product, YSCH-01, an oncolytic virus designed using the CTGVT strategy to replicate the genetic material specifically within tumor cells. This process leads to the destruction of cancerous cells and stimulates a healthy immune response.
Neural Stem Cell Therapeutics
iNStemCARE is dedicated to overcoming the scientific and regulatory challenges associated with developing neural stem cell therapies for rare and neurodegenerative diseases. The company is committed to continuous research and development, meticulously gathering and analyzing data to meet the stringent requirements of regulatory bodies..
Life Science AI
NeuroXess, a leading Chinese Brain-Computer Interface (BCI) company, specializes in flexible electrode technology to decode brain signals, facilitating applications like motor and speech restoration. Driven by a mission to advance human cognition and foster AI collaboration, NeuroXess is dedicated to groundbreaking neurological solutions and building international partnerships for future innovation..
Life Science AI
Life Code leverages an advanced AI drug discovery platform, integrating predictive analytics with in-house preclinical testing to accelerate the development of innovative treatments. Targeting unmet medical needs, it builds a robust portfolio of solutions across various therapeutic areas..
Drug Discovery and Development
Unlocking the Future of Precision Medicine and Beyond
TJ Bing, Partner, SVP, Head of Biology, ICE Bioscience Inc
Supplement Manufacturing
Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation
Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp [NASDAQ: RGEN]
Bioanalytical Services
Smart, Collective Measurement Is Key to Strengthening Healthcare Systems
Jessica Thongcharen, Director Global Patient Safety & Evaluation- Clinical Operations, Takeda [TYO: 4502]
Drug Discovery and Development
The simple things in life are still the best, even in clinical development
Ken Lee, General Manager and Region Head, Clinical Development, Asia Pacific, Syneos Health
Life Science Consulting
Charting a Trailblazing Path in Clinical Development
Maribelle Guloy, Director of Clinical Development, American Regent, Inc.
Drug Discovery and Development
Navigating Global R&D and Pharmacokinetics in Oncology
Rose Fida, Executive Director, Program & Performance Excellence, Global R&D Portfolio & Operations Excellence, CSL [ASX: CSL]
Therapeutics
Halal Biopharma: Closing the Therapeutic Gaps
Dr. Israfil Merican, MD, MHM, Director of Pharmaniaga Marketing Sdn Bhd, Pharmaniaga Berhad [KLSE: PHARMA]
Therapeutics
Bridging the Diversity Divide
Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]
Drug Discovery and Development
The Future of the Life Sciences Industry
Matthew (Matt) Hewitt, Executive Director, Scientific Solutions C and GT, Charles River Laboratories
IN MY OPINION
Therapeutics
Evolving Digital Biomarkers in Clinical Trial Space
Kazuto Yamada, Senior Director, Head of Clinical Development Planning and Supervising Five R&D Functions, Otsuka Pharmaceutical
LAST WORD
Life Science Consulting
Why a Quality Mindset Must Drive IT Change in Life Sciences
Paul Rascoe, Sr. Manager, IT SAP Systems, Beam Therapeutics
IN FOCUS
Translating CGT Research into Real-World Therapies in Japan
Japan is a global leader in cell and gene therapy, indicating a proactive regulatory framework that facilitates rapid access to innovative treatments for patients with unmet medical needs.
Smart Informatics in APAC's Biomanufacturing Revolution
The APAC biopharmaceutical sector is growing rapidly through R&D investments and advanced therapies, leveraging Smart Digital Biomedical Informatics for optimized cell culture media manufacturing and real-time monitoring.
EDITORIAL
Transforming Life Sciences: Innovation, Intelligence, And Next-Generation Therapeutics
At the same time, the way pharmaceutical information is communicated is also shifting. Modern translation workflows now integrate advanced neural machine translation with expert human oversight, ensuring medical content remains accurate, precise, and contextually relevant. As life sciences organizations scale globally, these language and communication services are becoming essential in supporting compliant and effective scientific exchange.
With these advancements shaping the industry, the global life sciences market is expected to grow at a CAGR of approximately 11.75 percent from 2024 to 2032.
In this edition of Life Sciences Review, we explore the evolving trends defining the sector and highlight companies delivering solutions aligned with the industry’s next phase of innovation.
This issue includes a thought leadership article by Kazuto Yamada, Senior Director and Head of Clinical Development Planning and Supervising Five R&D Functions at Otsuka Pharmaceutical, discussing how digital biomarkers are making clinical trials more patient-focused and efficient. Another article by TJ Bing, Head of Biology at ICE Bioscience Inc., provides insights into the growing need for stronger quality standards in the life sciences sector.
In this edition featuring Neural Stem Cell Therapeutics, AI Powered Life Sciences Technology, Brain-Computer Interface Technology Solution, and Therapeutics Company, we hope you find the right partners to support your organization’s goals.
